Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia

Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia in Patients Receiving Abdominal and Non-abdominal Surgeries.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04314310

Enrollment

Registered

2020-03-19

Start date

2020-03-23

Completion date

2025-12-31

Last updated

2020-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Recovery

Keywords

orocecal transmit time, flatus

Brief summary

breast cancer surgery is associated with a high incidence of persistant postsurgical pain (PPSP). The aim of the study was to evluate the impact of intravenous Tenoxicam on acute and PPSP, analgesic requirements and gastrointestinal recovery in patients undergoing surgery for breast cancer.

Detailed description

thrity patients participated in this randomized, single-blined study. Before and at the postoperative day 1, the bowel function (orocecal transmit time) were measured. Before induction of general anesthesia, patients recieved a bolus of intravenous Tenoxicam or an equal volume of saline (control group). Pain score and opioid consumption were recorded in the postoperative period and then daily for 1 week.

Interventions

DRUGTenoxicam

nonsteroidal anti-inflammatory drug (NSAID)

DRUGPlacebo

equal volume of normal saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Masking description

care provider and participant were masked

Intervention model description

treatment: Tenoxicam; control: placebo

Eligibility

Sex/Gender

FEMALE

Age

40 Years to 60 Years

Healthy volunteers

Inclusion criteria

* ASA I to II Breast cancer patients Mastectomy or wide local excision + axillary note dissection

Exclusion criteria

* Preexisting malignancy Chronic infection Previous pain condition Diabetes Thyroid disorder Severe cardiac, renal or hepatic disease Previous breast surgery Psychiatric illness Neurological disease Contraindication for tenoxicam or morphine use

Design outcomes

Primary

Measure	Time frame	Description
morphine consumption	until postoperative day7	morphine consumption after breast cancer surgery

Secondary

Measure	Time frame	Description
orocecal transmit time,	preoperative and postoperative day 1	smal intestinal function

Contacts

Primary ContactYa-Jung Cheng, MD,PhD

chengyj@ntu.edu.tw

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026